An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aptinyx to Participate in the 42nd Annual Cowen Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aptinyx Inc. (Nasdaq: APTX), a biopharmaceutical company, announced that CEO Andy Kidd will join the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 9:10 a.m. EST. A live webcast of the panel can be accessed on Aptinyx's website and will be available for 30 days post-event. The company focuses on developing small molecules to treat brain and nervous system disorders and has several candidates in clinical development for conditions like chronic pain and PTSD.
Positive
None.
Negative
None.
EVANSTON, Ill.--(BUSINESS WIRE)--
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference at 9:10 a.m. EST on Monday, March 7, 2022.
A live webcast of the panel discussion will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
